Prostate Cancer

Scope & Guideline

Transforming research into real-world impact for prostate cancer.

Introduction

Welcome to your portal for understanding Prostate Cancer, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2090-3111
PublisherHINDAWI LTD
Support Open AccessYes
CountryEgypt
TypeJournal
Converge2011, from 2013 to 2024
AbbreviationPROSTATE CANCER-US / Prostate Cancer
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON W1T 5HF, ENGLAND

Aims and Scopes

The journal 'Prostate Cancer' is dedicated to advancing knowledge and research in the field of prostate cancer, encompassing a wide range of topics from clinical treatment to psychosocial impacts. It aims to provide a platform for innovative research methodologies and significant findings that contribute to the understanding and management of prostate cancer.
  1. Clinical Treatment Strategies:
    Focuses on various treatment modalities for prostate cancer, including surgical, radiological, and pharmacological interventions, particularly in advanced stages such as castration-resistant prostate cancer.
  2. Diagnostic Innovations:
    Emphasizes the development and application of advanced diagnostic techniques, including imaging technology and machine learning, to enhance early detection and accurate staging of prostate cancer.
  3. Patient-Centered Research:
    Explores the psychosocial and health-related quality of life factors affecting patients, integrating patient-reported outcomes to better understand the impact of prostate cancer treatments.
  4. Neurocognitive Effects of Treatment:
    Investigates the cognitive side effects associated with prostate cancer therapies, particularly androgen deprivation therapy, to address the overall well-being of patients.
  5. Longitudinal Health Studies:
    Utilizes large-scale cohort studies to analyze trends in diagnosis, treatment outcomes, and factors influencing prostate cancer progression.
In recent publications, several emerging themes have become increasingly prominent within the journal 'Prostate Cancer'. These reflect contemporary challenges and advancements in the field, highlighting areas of growing importance for future research.
  1. Integration of AI in Diagnostics:
    The use of artificial intelligence and machine learning techniques for improving diagnostic accuracy and treatment personalization is rapidly gaining traction, indicating a shift toward more technologically advanced methodologies.
  2. Impact of Treatment on Quality of Life:
    Research focusing on the psychosocial aspects and quality of life post-treatment is on the rise, underscoring the importance of holistic patient care beyond mere survival rates.
  3. Longitudinal Studies on Patient Outcomes:
    There is an increasing trend in conducting longitudinal studies to track patient outcomes over time, providing valuable insights into the long-term effects of treatments and lifestyle factors on prostate cancer progression.
  4. Neurocognitive Research:
    Studies assessing the cognitive effects of prostate cancer treatments, particularly androgen deprivation therapy, are becoming more prominent, recognizing the broader implications of cancer therapies on patient mental health.

Declining or Waning

While the journal covers a broad array of topics, certain themes have shown a decline in focus over recent years. This reflects a shift in research priorities and emerging challenges in the field of prostate cancer management.
  1. Traditional Surgical Techniques:
    There appears to be a reduced emphasis on traditional surgical methods as newer, less invasive treatments gain attention and acceptance among researchers and clinicians.
  2. Basic Science Research:
    Research centered on the basic biological mechanisms of prostate cancer is becoming less prominent, possibly due to a stronger focus on clinical applications and patient-centered studies.
  3. Pharmacological Studies on Older Agents:
    There is a noticeable decrease in publications related to older pharmacological agents, as current research trends favor newer therapies that target specific pathways or utilize novel mechanisms.

Similar Journals

EUROPEAN UROLOGY

Advancing urological science for a healthier tomorrow.
Publisher: ELSEVIERISSN: 0302-2838Frequency: 12 issues/year

EUROPEAN UROLOGY is a prestigious journal in the field of urology, published by Elsevier, and residing in the vibrant academic landscape of the Netherlands. Since its inception in 1975, the journal has made significant contributions to urological research, earning a top rank of #1 out of 120 in the Scopus category of Medicine - Urology, placing it within the esteemed 99th percentile of its field. With a commitment to disseminating cutting-edge research, clinical findings, and innovative practices, EUROPEAN UROLOGY has established itself as a pivotal resource for urologists and researchers alike. Although it does not offer open access options, it provides an indispensable platform for scholarly communication that drives advancements in patient care and medical knowledge. As the journal embarks on converged years leading up to 2024, it continues to strive for excellence in urology, welcoming contributions that reflect the latest scientific advancements and clinical applications.

PROSTATE CANCER AND PROSTATIC DISEASES

Advancing knowledge in prostate health and disease.
Publisher: SPRINGERNATUREISSN: 1365-7852Frequency: 4 issues/year

PROSTATE CANCER AND PROSTATIC DISEASES, published by SpringerNature, is a prestigious international journal dedicated to advancing knowledge in the fields of cancer research, oncology, and urology, as evidenced by its Q1 rankings in 2023. Established in 1997, this journal has become a vital resource for researchers, clinicians, and healthcare professionals, offering impactful research and clinical insights on prostate health and disease. With its focus on innovative studies and comprehensive reviews, it addresses critical challenges in the management and treatment of prostate cancer, driving improvements in patient care globally. The journal's standing is further supported by its impressive Scopus rankings, placing it in the top tier of its categories. Readers can access high-quality, peer-reviewed articles that contribute significantly to ongoing medical practices and improve therapeutic strategies for prostate-related health issues.

Current Urology

Bridging Theory and Practice in Urology and Beyond
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1661-7649Frequency: 4 issues/year

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

UROLOGY

Fostering Collaboration in Urological Advancements
Publisher: ELSEVIER SCIENCE INCISSN: 0090-4295Frequency: 12 issues/year

UROLOGY is a prestigious journal published by Elsevier Science Inc, renowned for disseminating high-quality research and reviews in the field of urology. With an ISSN of 0090-4295 and E-ISSN 1527-9995, this journal has been a trusted resource since its inception in 1973 and continues to provide insights into the latest advancements and clinical practices in urology, maintaining a category quartile of Q2 as of 2023. The journal ranks 50th out of 120 in the Scopus metrics for Medicine - Urology, placing it in the 58th percentile, which underscores its influence and relevance in the academic community. Although it is not structured as an open access journal, it offers a wealth of knowledge vital for researchers, healthcare professionals, and students alike, enabling them to stay abreast of evolving treatments and innovations in the field. As we move towards 2024, UROLOGY remains committed to advancing research and enhancing practices in urological care, fostering a collaborative environment among its readership.

Actas Urologicas Espanolas

Innovating Urology: From Research to Practice
Publisher: ELSEVIER ESPANAISSN: 0210-4806Frequency: 10 issues/year

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

Frontiers in Oncology

Innovating oncology through open access and collaboration.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

European Urology Oncology

Delivering high-quality, peer-reviewed content for medical excellence.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Investigative and Clinical Urology

Exploring the frontiers of urology for enhanced patient care.
Publisher: KOREAN UROLOGICAL ASSOCISSN: 2466-0493Frequency: 6 issues/year

Investigative and Clinical Urology is an esteemed open-access journal dedicated to advancing research and clinical practice in the field of urology. Published by the Korean Urological Association, this journal serves as a crucial platform for sharing innovative findings and discussions on urological science, treatments, and technologies. With an ISSN of 2466-0493 and an E-ISSN of 2466-054X, it has established its presence in the academic community since transitioning to open access in 2016. Positioned in the Q2 quartile of urology journals for 2023 and ranked 39th out of 120 in Scopus's urology category, it reflects a strong impact in the field with a 67th percentile ranking. This journal not only facilitates broad accessibility to high-quality research but also fosters collaboration and dialogue among researchers, professionals, and students interested in the latest advancements in urology. Operating from Seoul, South Korea, Investigative and Clinical Urology remains a pivotal resource for anyone seeking to enhance their understanding and practice in urological medicine.

BMC Urology

Advancing Urological Insights for a Healthier Tomorrow
Publisher: BMCISSN: 1471-2490Frequency: 1 issue/year

BMC Urology is a premier open-access journal dedicated to advancing research in the field of urology, reproductive medicine, and miscellaneous aspects of medicine. Published by BMC since 2001 and based in the United Kingdom, this journal provides a platform for researchers, clinicians, and students to disseminate their findings and explore the latest innovations and advancements within these vital fields. With a notable impact factor and categorization in the Q2 quartile for various categories of medicine, BMC Urology stands as a reputable source, ranking 51st out of 120 in Urology and 44th out of 90 in Reproductive Medicine according to Scopus metrics. The journal fosters knowledge sharing through its open-access model, ensuring that research is accessible to all. As it converges from 2001 to 2024, BMC Urology continues to play a crucial role in shaping the landscape of urological research and providing invaluable insights into clinical practices.

Canadian Journal of Urology

Leading the way in urology research and clinical excellence.
Publisher: CANADIAN J UROLOGYISSN: 1195-9479Frequency: 6 issues/year

Canadian Journal of Urology, published by CANADIAN J UROLOGY, is a prominent peer-reviewed journal dedicated to advancing the field of urology and its allied disciplines. Established in 2000, this journal has consistently aimed to provide a platform for comprehensive research, clinical studies, and innovative practices in urology and general medicine, ensuring that professionals remain at the forefront of medical advancements. With a reputation reflected in its 2023 Scopus ranking of Q3 in both Urology and Medicine (miscellaneous), the journal serves as an essential resource for researchers and practitioners seeking to enhance their knowledge and application of urological sciences. Although it is not an Open Access journal, its impactful findings contribute significantly to the medical community in Canada and beyond, promoting evidence-based practices and contributing to better patient outcomes. As the journal converges into 2024, it continues to welcome high-quality submissions that explore critical challenges and advancements in urology.